Pharmaceuticals & Biologics

OCR 5199

Yale researchers have identified that the acute inflammatory response to biomaterials can be limited by inhibition of inflammasome-related pathways.

OCR 57674445

Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases. Semaphorin 7A inhibition is also effective as a therapeutic treatment for fibrotic disease.

OCR 6320
OCR6320 is a safe and efficacious novel vaccine candidate for the treatment of Leptospira infections.
OCR 6185

Yale researchers created an inactivated version of the thyphoid toxin, which can serve as the basis for the development of novel second-generation vaccines to treat typhoid fever.

OCR 1642

GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.

OCR 1617

Scientists at Yale have successfully demonstrated therapeutic efficacy of a monoclonal antibody targeting CCR5 in an animal model for Chronic Obstructive Pulmonary Disease (COPD).

OCR 5478

Researchers at Yale have discovered a new indication for a clinical stage, cell penetrating antibody that can enhance the therapeutic effect of radiation therapy or DNA-damaging chemotherapy agents. This antibody treatment can increase tumor cell sensitivity to either radiation therapy or chemotherapy by more than 60%, and may result in a decreased amount of cancer therapy needed to kill cells and reduce the resulting toxic side effects. The antibody is also effective, by itself, against BRCA-deficient cancer cells.

OCR 1674

A collaborative research effort, performed in part with Yale, has identified a unique method to induce the formation of new bone in targeted skeletal sites, as well as accelerate and secure the repair process of fractures.